UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 23, 2018

 

PROPHASE LABS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   0-21617   23-2577138
(State or other jurisdiction
of incorporation)
  (Commission
file number)
  (I.R.S. Employer
Identification No.)

 

621 N. Shady Retreat Road, Doylestown, PA, 18901

(Address of principal executive offices)

 

(Registrant’s telephone number, including area code): (215) 345-0919

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-2)
   
[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240. 13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company [  ]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

 

 

 

 
 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Approval of Amended and Restated 2010 Equity Compensation Plan and Amended and Restated 2010 Director’ Equity Compensation Plan

 

On May 23, 2018, the stockholders of ProPhase Labs, Inc. (the “Company”) approved the Amended and Restated 2010 Equity Compensation Plan (the “Amended 2010 Plan”) and the Amended and Restated 2010 Directors’ Equity Compensation Plan (the “Amended 2010 Directors’ Plan”) at the 2018 Annual Meeting of Stockholders of the Company (the “2018 Annual Meeting”). The Amended 2010 Plan and the Amended 2010 Directors’ Plan has been previously approved by the board of directors of the Company on April 12, 2018, subject to stockholder approval at the 2018 Annual Meeting.

 

The Amended 2010 Plan provides for an increase in the number of shares reserved for issuance under the plan by 700,000 shares, from 3,200,000 shares to 3,900,000 shares, and allows the board of directors to grant restricted stock awards and restricted stock units thereunder.

 

The Amended 2010 Directors’ Plan provides for an increase in the number of shares reserved for issuance under the plan by 250,000 shares, from 425,000 shares to 675,000 shares, and allows the board of directors to grant restricted stock awards and restricted stock units thereunder.

 

The foregoing description of the Amended 2010 Plan and Amended 2010 Directors’ Plan is qualified in its entirety by reference to the full text of the Amended 2010 Plan and Amended 2010 Directors’ Plan, which are attached hereto as Exhibit 10.1 and Exhibit 10.2, respectively, and the terms of which are incorporated by reference in this Item 5.02.

 

Approval of Cash Bonus to Monica Brady

 

On May 23, 2018, the Compensation Committee and the board of directors of the Company approved a discretionary cash bonus payment to Monica Brady, the Company’s Chief Accounting Officer, in the amount of $10,000, in recognition of her contributions to the Company.

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

The final voting results of the matters voted on at the 2018 Annual Meeting are provided below.

 

Proposal 1. Election of Directors

 

Each of the nominees for election to the board of directors was elected to hold office for a one-year term and until their respective successors are elected and qualified by the following votes:

 

Name  For  Withheld  Broker Non-
Votes
Ted Karkus  8,881,327  27,683  2,079,117
Jason Barr  8,857,699  51,311  2,079,117
Mark Burnett  8,859,849  49,161  2,079,117
Louis Gleckel, MD  8,816,657  92,353  2,079,117

 

Proposal 2. Ratification of the Appointment of Independent Auditors

 

The ratification of the appointment by the Audit Committee of the board of directors of EisnerAmper LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018 was approved by the following vote:

 

For  Against  Abstain  Broker Non-
Votes
10,923,148  44,581  20,398  0

 

- 2 -
 

 

Proposal 3. Approval of the Amended and Restated 2010 Equity Compensation Plan

 

The Amended 2010 Plan was approved by the following vote:

 

For  Against  Abstain  Broker Non-
Votes
8,625,167  279,276 

4,567

  2,079,117

 

Proposal 4. Approval of the Amended and Restated 2010 Directors’ Equity Compensation Plan

 

The Amended Directors’ 2010 Plan was approved by the following vote:

 

For  Against  Abstain  Broker Non-
Votes
8,609,791 

293,964

  5,255  2,079,117

 

Item 9.01. Financial Statements and Exhibits

 

(d) Exhibits

 

Exhibit No.   Description
     
10.1   Amended and Restated 2010 Equity Compensation Plan
     
10.2   Amended and Restated 2010 Directors’ Equity Compensation Plan

 

- 3 -
 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ProPhase Labs, Inc.
     
  By: /s/ Ted Karkus 
    Ted Karkus
    Chairman of the Board,
Chief Executive Officer and Director

 

Date: May 24, 2018

 

- 4 -